Genflow's SIRT6 gene therapy reduced biological age in senior beagles as measured by DNA methylation clocks, meeting its primary trial endpoint. This result positions companion animal studies as a practical bridge between basic aging research and human therapeutic development, potentially accelerating the path to human trials for gene therapies targeting age-related decline.
Key Points
- SIRT6 gene therapy lowered biological age in treated beagles versus controls
- DNA methylation clocks confirmed measurable reversal of aging markers
- Companion animal trials offer real-world aging model faster than rodent studies
Longevity Analysis
Gene therapy targeting SIRT6—a variant enriched in centenarians—demonstrates that age-related cellular decline can be partially reversed rather than merely slowed. The trial's use of established epigenetic clocks to measure biological age independently of chronological time represents a meaningful advancement in how aging interventions are validated. Because dogs age on a compressed timeline while sharing metabolic and environmental stressors with humans, this study provides evidence that would take decades to accumulate in humans alone. The results suggest a shift in therapeutic strategy: delivering genetic variants associated with human longevity directly into aged tissue, rather than developing symptomatic treatments. This approach targets the mechanisms of aging itself, not its downstream consequences.
Original published by Longevity.Technology, by Eleanor Garth.